Lonza

We are proud to announce that we have again earned a Silver medal in the EcoVadis Sustainability Rating, with our score (72/100 points) increasing 6 points from last year’s score. This year, we saw significant improvements in our Labor and Human Rights pillar and our Sustainable Procurement pillar. Sustainability is deeply embedded in our operations and mindset. Our stakeholders - colleagues, customers, and investors - demand transparency regarding our sustainable practices. Our mission to enable a healthier world extends beyond customer treatments and therapies; it encompasses our entire ESG impact. Find out more about our Sustainability goals and achievements here: https://lnkd.in/dXRf8sh #AMeaningfulDifference #Sustainability #Ecovadis #ESG

Dose flexibility is increasingly important for companies planning to run early stage clinical trials, particularly for cancer medicines and dosages designed for children. Two of Lonza’s experts in the area will be giving a webinar about the topic, explaining why it’s important and how it can be achieved. Jonathan Cape and Kaylee Eyerly will explain when and how multiple doses or dose flexibility are appropriate. They’ll describe how to select the best delivery and manufacturing technologies to give dose flexibility, and do so while meeting cost and timeline constraints. The webinar is on Tuesday, 27 August, at 11am EDT/5pm CEST. You can register for free here: https://lnkd.in/eN26J9tN #LonzaSM #Multiparticulates #DoseFlexibility #ProjectOptimus

Champalimaud Foundation, a biomedical clinical research organization, has just installed Lonza’s MODA-ES® Platform at the Champalimaud Clinical Centre in Lisbon, Portugal. Through the installation of MODA-ES®, the Champalimaud Foundation plans to improve and streamline the cell therapy manufacturing process, thereby increasing accessibility of life-saving therapies for patients with cancer with unmet medical needs. MODA-ES® is designed specifically for cell and gene therapy production. It consolidates all manufacturing batch and batch-related quality control data into a single record for reduced errors, greater visibility, and expedited product release. The platform provides advanced traceability and genealogy workflows, which helps to ensure the chain of identity and custody in complex decentralized cell and gene therapy manufacturing processes. Find out more here: https://lnkd.in/dGd535u3 #AHealthierWorld #CellTherapy #GeneTherapy #Paperless #LonzaMODA

Our Cocoon® Platform now integrates Akadeum Life Sciences® Buoyancy-Activated Cell Sorting (BACS™) technology for negative T cell selection directly from Leukopaks. Alongside our positive selection capabilities, this cutting-edge feature enables the isolation, modification, and expansion of T cells in a fully automated, functionally closed system. By enriching T cells without direct biochemical interaction, we preserve their innate, unstimulated state, allowing for customized activation strategies. Discover how this innovation can transform your T cell workflows. Read our latest application note to learn more: https://lnkd.in/dRTsJCdf #CellTherapy #GeneTherapy #LonzaCGT #RealizingPotentialTogether

Lonza expert Simon Wagschal and Elsevier Information Systems’ Juergen Swienty-Busch recently gave a webinar about how AI is being used to address the growing complexity of APIs. It’s an increasing problem, as the synthetic routes required to make them are getting longer, too, making it more difficult to adhere to demanding development timelines.   In the webinar, they looked at how Lonza’s new AI-Enabled Route Scouting service is combining computer-aided synthesis planning tools with our expertise, experience and supply chain knowledge to find better, faster synthetic routes for our customers.   The webinar is now available to watch on demand: https://lnkd.in/eC4XSvtU   #LonzaSM #RouteScouting #AI #APIComplexity

We have just announced the addition of clinical bottling and labeling capabilities at our Small Molecules site in Bend, Oregon (US). The new equipment can detect defects in tablets and capsules as well as clean, fill, cap and seal, and label bottles intended for use in early-phase clinical trials. This enables us to speed up product delivery to clinical trial centers, which is crucial in its customers' journey toward clinical trials. Read more about our upgraded clinical manufacturing services here: https://lnkd.in/db57gpX9 #AHealthierWorld #WeWorkAsOne #PharmaceuticalManufacturing #SpeedToClinic #ClinicalTrials

We are proud to announce we are now a member of Advance – Gender Equality in Business, a network of companies committed to increasing the proportion of women in management. Advance is the leading business association for gender equality in Switzerland, with a network of 145 Swiss-based companies committed to increasing the proportion of women in management. Advance aims to achieve a sustainable minimum of 30% female representation at all management levels across all member companies by 2030. This goes hand-in-hand with, and will help us achieve, our own Sustainable Development Goal (SDG5) of 35% female leadership by 2035. As a member of Advance, we become part of a network of companies with the same goal. #AMeaningfulDifference #SDG5 #WomenInLeadership #GenderEquality

Highly potent active pharmaceutical ingredients, or HPAPIs, are a key capability for Lonza Small Molecules. They’re growing in importance in the pharmaceutical industry, with more than 1000 currently in development. But manufacturing them poses a range of technical and safety considerations. Lonza Small Molecules senior director Charlie Johnson has just had an article published in Speciality Chemicals magazine that explains the challenges involved in making HPAPIs, and how CDMOs like Lonza can help. Making HPAPIs requires a significant investment in containment equipment, and expert operators to run them. This is something Lonza has put a substantial focus on in recent years, leaving us well placed to assist customers with their HPAPI projects. If you’d like to know more about the challenges involved in making HPAPIs, you can read Charlie’s article in the magazine online. It’s on page 16. And do get in touch with us if you’d like to discover how Lonza Small Molecules can help make your HPAPI a reality. https://lnkd.in/ee_HXNUz #LonzaSM #HPAPI #HPAPITrends #ADC #SpecialityChemicals #Outsourcing

In Focus - our July edition of the biologics newsletter from Lonza is ready for you to read. Each month, we deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real-world customer stories.  This month's highlights include: - News article: Patronus Progresses to Clinical Trials for Herpes Zoster Vaccine, Expressed Using Lonza’s CHOK1SV GS-KO® Cell Line and GS piggyBac® Technology - Webinar: Advancing Early-Stage Bispecific Discovery Programs Towards Clinical Success - An article: Considerations for Successful Tech Transfer of a Biologic Purification Process Remember to subscribe to ensure you receive future editions of Biologics In Focus. #LonzaBio #Pharma #Biotechnology #thePeoplePoweringBiologics

Today we reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with our business performance well on track to deliver our Full-Year Outlook.   Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. We welcomed Jean-Marc Huët as our new Chairman of the Board in May, and welcomed Wolfgang Wienand as our new CEO in July.   We also continued to make progress on our ESG commitments. Our emissions targets were validated by the Science Based Targets initiative (SBTi) in the First Half, and we signed a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026.   Read more about our progress in H1 2024 here: https://lnkd.in/diMHZF9m   #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults